Free tool
Oncology stocks
We cover 114 companies grouped under the Oncology theme. The median market value in the group is $505.70M. Across the group, the median move over the past trading day is 0.00%. 62% of the 110 with a 200-day average trade above it. Price change over the past year runs from −35.2% to +221.1% across the middle 80 percent of the group, with a median of +25.8%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
114 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $71.92B | Large cap | +9.21% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| 4568.T | Daiichi Sankyo Company, Limited | $32.82B | Large cap | −17.94% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% |
| GXE.DE | Lakefront Biotherapeutics NV | $1.93B | Small cap | −44.50% |
| IMCR | Immunocore Holdings plc | $1.93B | Small cap | +13.69% |
| DMRA | Damora Therapeutics, Inc. | $1.89B | Small cap | +804.46% |
| VIR | Vir Biotechnology, Inc. | $1.87B | Small cap | +111.85% |
| INBX | Inhibrx Biosciences, Inc. | $1.81B | Small cap | +357.45% |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.77B | Small cap | +23.55% |
| BCAX | Bicara Therapeutics Inc. | $1.64B | Small cap | +105.74% |
| AAPG | Ascentage Pharma Group Internat | $1.58B | Small cap | −59.18% |
| AVBP | ArriVent BioPharma, Inc. | $1.54B | Small cap | +62.10% |
| REPL | Replimune Group, Inc. | $1.50B | Small cap | +187.16% |
| CGEM | Cullinan Therapeutics, Inc. | $1.48B | Small cap | +188.15% |
| AKTS | Aktis Oncology, Inc. | $1.47B | Small cap | +18.35% |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.44B | Small cap | +35.58% |
| IMTX | Immatics N.V. | $1.41B | Small cap | +74.63% |
| DRTS | Alpha Tau Medical Ltd. | $1.38B | Small cap | +343.92% |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.23B | Small cap | +207.92% |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.22B | Small cap | +167.82% |
| KURA | Kura Oncology, Inc. | $1.16B | Small cap | +66.16% |
| JANX | Janux Therapeutics, Inc. | $1.15B | Small cap | −19.10% |
| 2160.T | GNI Group Ltd. | $1.14B | Small cap | +8.36% |
| PHIL.MI | Philogen S.p.A. | $1.11B | Small cap | +4.75% |
| CADL | Candel Therapeutics, Inc. | $1.02B | Small cap | +124.70% |
| GERN | Geron Corporation | $995.83M | Small cap | +8.51% |
| EUZ.DE | Eckert & Ziegler SE | $952.11M | Small cap | −24.60% |
| OLMA | Olema Pharmaceuticals, Inc. | $949.35M | Small cap | +89.02% |
| 4587.T | PeptiDream Inc. | $891.51M | Small cap | −27.31% |
| ANL | Adlai Nortye Ltd. | $884.83M | Small cap | +791.12% |
| RIGL | Rigel Pharmaceuticals, Inc. | $864.97M | Small cap | +16.99% |
| NVCT | Nuvectis Pharma, Inc. | $816.10M | Small cap | +275.94% |
| AURA | Aura Biosciences, Inc. | $801.64M | Small cap | +20.03% |
| MNPR | Monopar Therapeutics Inc. | $763.31M | Small cap | +226.69% |
| 4588.T | Oncolys BioPharma Inc. | $753.78M | Small cap | +539.50% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $751.23M | Small cap | −0.43% |
| CTMX | CytomX Therapeutics, Inc. | $723.43M | Small cap | +60.39% |
| GUD.TO | Knight Therapeutics Inc. | $690.78M | Small cap | +50.39% |
| EIKN | Eikon Therapeutics, Inc. | $679.77M | Small cap | −20.13% |
| SGMT | Sagimet Biosciences Inc. | $675.04M | Small cap | +39.59% |
| CBIO | Crescent Biopharma, Inc. | $669.39M | Small cap | +26.46% |
| VSTM | Verastem, Inc. | $641.19M | Small cap | −20.45% |
| CU6.AX | Clarity Pharmaceuticals Ltd | $628.73M | Small cap | −25.63% |
| ARVN | Arvinas, Inc. | $609.40M | Small cap | +15.35% |
| DCTH | Delcath Systems, Inc. | $569.06M | Small cap | +49.91% |
| PRLD | Prelude Therapeutics Incorporated | $522.47M | Small cap | +412.50% |
| CCCC | C4 Therapeutics, Inc. | $521.63M | Small cap | +64.34% |
| TOI | Starling Oncology Inc | $512.91M | Small cap | +79.19% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | $498.50M | Small cap | −90.91% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | $492.64M | Small cap | +1198.08% |
| RLMD | Relmada Therapeutics, Inc. | $485.35M | Small cap | +579.10% |
| PBYI | Puma Biotechnology, Inc. | $472.84M | Small cap | +79.61% |
| AVCT.L | Avacta Group Plc | $440.62M | Small cap | +26.36% |
| CMPX | Compass Therapeutics, Inc. | $437.61M | Small cap | −25.91% |
| FRX.TO | Fennec Pharmaceuticals Inc. | $429.52M | Small cap | +36.00% |
| FENC | Fennec Pharmaceuticals Inc. | $426.77M | Small cap | +34.62% |
| GALT | Galectin Therapeutics Inc. | $418.53M | Small cap | +4.27% |
| PRTC.L | PureTech Health plc | $398.28M | Small cap | −4.27% |
| FHTX | Foghorn Therapeutics Inc. | $397.29M | Small cap | +23.66% |
| AGEN | Agenus Inc. | $371.33M | Small cap | +81.72% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $368.27M | Small cap | +113.74% |
| CATX | Perspective Therapeutics, Inc. | $360.72M | Small cap | −12.47% |
| STRO | Sutro Biopharma, Inc. | $355.50M | Small cap | +138.11% |
| IMRX | Immuneering Corporation | $333.19M | Small cap | −0.77% |
| RAC.AX | Racura Oncology Ltd | $312.81M | Small cap | +87.39% |
| BCYC | Bicycle Therapeutics plc | $304.03M | Small cap | −37.79% |
| PYXS | Pyxis Oncology, Inc. | $278.58M | Small cap | +145.59% |
| WHWK | Whitehawk Therapeutics, Inc. | $275.92M | Small cap | +167.40% |
| ALXO | ALX Oncology Holdings Inc. | $273.79M | Small cap | +65.00% |
| CGEN | Compugen Ltd. | $271.86M | Small cap | +93.20% |
| GLSI | Greenwich LifeSciences, Inc. | $267.58M | Small cap | +56.21% |
| TNG.PA | Transgene SA | $263.11M | Small cap | −22.50% |
| ADAG | Adagene Inc. | $258.50M | Small cap | +75.80% |
| MGNX | MacroGenics, Inc. Common Stock | $257.35M | Small cap | +134.88% |
| IPHA | Innate Pharma S.A. | $253.56M | Small cap | +2.86% |
| SPL.AX | Starpharma Holdings Limited | $248.56M | Small cap | +437.04% |
| IDD.DE | Innate Pharma S.A. | $243.27M | Small cap | −2.52% |
| IPH.PA | Innate Pharma S.A. | $240.15M | Small cap | +1.19% |
| TARA | Protara Therapeutics, Inc. | $231.06M | Small cap | +21.05% |
| CHRS | Coherus Oncology, Inc. | $224.03M | Small cap | +27.19% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $218.56M | Small cap | +7.93% |
| NBP | NovaBridge Biosciences | $216.26M | Small cap | −58.44% |
| CUE | Cue Biopharma, Inc. | $209.58M | Small cap | +16.42% |
| MOLN | Molecular Partners AG | $170.46M | Small cap | +18.67% |
| MENS | Jyong Biotech Ltd. | $170.30M | Small cap | −95.62% |
| KZIA | Kazia Therapeutics Limited | $166.83M | Small cap | +86.94% |
| BINV.ST | BioInvent International AB (publ) | $162.35M | Small cap | −23.46% |
| OKUR | OnKure Therapeutics, Inc. | $155.52M | Small cap | +35.71% |
| ASRT | Assertio Holdings Inc | $151.86M | Small cap | +103.46% |
| INDP | Indaptus Therapeutics, Inc. | $145.90M | Small cap | −82.19% |
| SCLP.L | Scancell Holdings plc | $136.80M | Small cap | −7.62% |
| HURA | TuHURA Biosciences, Inc. | $135.74M | Small cap | −26.55% |
| HPHA.DE | Heidelberg Pharma AG | $135.27M | Small cap | −31.15% |
| ADCT | ADC Therapeutics SA | $134.05M | Small cap | −67.39% |
| BDTX | Black Diamond Therapeutics, Inc. | $130.42M | Small cap | −20.91% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $124.97M | Small cap | +80.49% |
| GNLX | Genelux Corporation | $123.52M | Small cap | −25.00% |
| ANIX | Anixa Biosciences, Inc. | $122.65M | Small cap | +22.20% |
| NTHI | NeOnc Technologies Holdings, Inc. | $122.16M | Small cap | −29.30% |
| RVU.WA | Ryvu Therapeutics S.A. | $115.61M | Small cap | −36.99% |
| 4889.T | Renascience Inc. | $112.48M | Small cap | −40.80% |
| FARN.L | Faron Pharmaceuticals Oy | $110.28M | Small cap | −79.24% |
| ONCY | Oncolytics Biotech Inc. | $109.10M | Small cap | −19.28% |
| HBP.TO | Helix BioPharma Corp. | $106.76M | Small cap | +46.97% |
| 4575.T | CanBas Co., Ltd. | $103.86M | Small cap | −30.98% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.